Journey Medical launches Emrosi for rosacea; first prescriptions filled

Journey Medical Corp

Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.
First prescriptions filled; initial distribution to specialty pharmacy chains ongoing.
FDA approval was obtained in November 2024; Emrosi is the lowest-dose oral minocycline for rosacea.
Clinical trials showed significantly superior outcomes vs. Oracea and placebo with comparable safety.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.